Medivation Price Target Increased to $65.00 by Analysts at Barclays (MDVN)
Analysts at Barclays raised their target price on shares of Medivation (NASDAQ:MDVN) from $62.00 to $65.00 in a research report issued to clients and investors on Friday, Analyst Ratings Network reports. Barclays’ target price indicates a potential downside of 0.17% from the company’s current price.
A number of other analysts have also recently weighed in on MDVN. Analysts at Aegis reiterated a “positive” rating on shares of Medivation in a research note on Tuesday. Separately, analysts at Ned Davis Research upgraded shares of Medivation from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Finally, analysts at Canaccord Genuity initiated coverage on shares of Medivation in a research note on Wednesday, April 16th. They set a “hold” rating and a $60.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company. Medivation has an average rating of “Hold” and a consensus target price of $90.69.
Medivation (NASDAQ:MDVN) opened at 65.11 on Friday. Medivation has a 1-year low of $44.51 and a 1-year high of $88.20. The stock’s 50-day moving average is $61.11 and its 200-day moving average is $67.03. The company’s market cap is $4.970 billion.
Medivation (NASDAQ:MDVN) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.09. The company had revenue of $87.19 million for the quarter, compared to the consensus estimate of $94.64 million. During the same quarter in the previous year, the company posted ($0.36) earnings per share. The company’s revenue for the quarter was up 88.9% on a year-over-year basis. On average, analysts predict that Medivation will post $0.72 earnings per share for the current fiscal year.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.